Pharmstandard OJSC / Bever Pharmaceutical Pte Ltd

Antiviral (Influenza) and Anxiolytic OTC Franchises (Russia/CIS)

Disease Overview

Arbidol (umifenovir) is a Russian/Chinese-marketed broad-spectrum antiviral indicated for influenza A/B and other respiratory viral infections, working by inhibiting viral envelope-cell membrane fusion; efficacy outside Russia/China is contested and a 2021 systematic review of COVID-19 studies found no significant benefit. Aphobazolum (fabomotizole) is a non-benzodiazepine anxiolytic developed in Russia for generalized anxiety disorder.

Competitive Landscape

The Russian/CIS antiviral OTC market is led domestically by Pharmstandard's Arbidol and ingavirin (Valenta), with limited Western-branded antivirals (Tamiflu/oseltamivir from Roche, Relenza/zanamivir from GSK) at far higher price points. The Russian anxiolytic market is dominated by domestic and Eastern European players (Valenta's Tenoten, Pharmstandard's Aphobazol) plus generic benzodiazepines. Both Arbidol and Aphobazol have minimal Western regulatory recognition and weak independent efficacy evidence — Arbidol is not FDA-approved and was excluded from WHO COVID-19 antiviral recommendations. The Bever transaction was structured to vertically secure long-term fixed-cost API supply for these two flagship OTC franchises, which together drove a meaningful share of Pharmstandard's OTC revenue. The deal was poorly received: shares fell ~25% on announcement and the company lost ~$1.4B (~45%) of market cap by mid-July 2013, with VTB Capital analyst Ivan Kushch publicly calling the related-party structure 'poor corporate governance practice' because Bever was 100% controlled by Bristley Enterprises (owned by Pharmstandard non-executive director Dr. Alexander Shuster), who became Pharmstandard's second-largest shareholder (~18.74%) on closing. The deal mattered less for therapeutic competition than as a governance cautionary tale and as the catalyst for Pharmstandard's separation of its OTC business from its Rx franchise.